BioLargo Earnings Call Transcripts
Fiscal Year 2026
-
The presentation outlined a diversified portfolio of transformative technologies in battery storage, infection control, and PFAS remediation, each positioned for market leadership and monetization. Key assets are entering adoption and commercialization phases, with major partnerships, regulatory milestones, and financing events expected in the next six months.
Fiscal Year 2025
-
2025 saw a revenue decline to $7.8M and a $15.2M net loss, mainly due to the Pooph license termination, but strong liquidity and service revenue growth were maintained. Clyra Medical entered commercialization, AEC achieved regulatory validation, and Cellinity Battery advanced joint ventures, positioning for a transformative 2026.
-
Q3 results were impacted by a $3.85M Pooph credit loss, halving revenue year-over-year, but strong cash reserves and ongoing investment in CLYRA and battery tech position the company for future growth. PFAS and battery segments achieved technical milestones, with major commercialization steps expected soon.
-
A diversified innovation portfolio is advancing in energy storage, medical tech, and environmental solutions, with major launches and global partnerships underway. The company is scaling battery factory licensing, addressing supply chain and safety gaps, and expects significant value realization as assets reach market adoption.
-
Q2 2025 revenue declined 40% year-over-year to $3 million, but service revenues and margins improved. Clyra Medical is preparing for a major product launch, and battery tech is advancing toward global joint ventures. Uncertainty remains around POOPH and Ikigai payments.
-
The conference highlighted a portfolio of advanced environmental and health technologies nearing commercialization, including a transformative medical device, a high-density salinity battery with a global franchise model, and PFAS water treatment solutions. Key assets are positioned for significant revenue growth and potential exits in the next 1–2 years.
-
The event highlighted a mission-driven approach to innovation in health, energy, and environmental tech, with key product launches and commercial milestones expected in the next year. Battery and PFAS solutions are positioned for global scale, leveraging partnerships and a capital-efficient model.
-
Revenue fell to $3.3M from $4.7M year-over-year, with net loss widening to $1.9M, mainly due to lower Pooph sales and higher non-cash expenses. Clyra and Solinity battery tech are positioned for growth, with major investments and third-party validation underway.
-
A refined innovation-driven model supports four operating units in high-impact markets, including odor control, infection control, PFAS remediation, and advanced batteries. Key products are scaling rapidly, with major partnerships, strong financial performance, and new tech validation underway.
-
Innovative environmental solutions are driving strong revenue growth, with advanced PFAS removal and non-toxic odor control technologies gaining commercial traction. Strategic partnerships and global expansion support a mission of sustainability and regulatory leadership.
Fiscal Year 2024
-
Revenue grew 45% year-over-year to nearly $18M, driven by strong Pooph sales and progress in Clyra Medical, battery tech, and PFAS solutions. Net loss narrowed, cash and equity improved, and key product launches and validations are imminent, supporting a positive outlook.
-
Record nine-month revenue of $14M and strong cash position highlight robust growth, with Clyra's large-scale launch and battery tech partnerships set for 2025. PFAS and POOPH segments continue to drive value, while uplisting and further expansion are targeted for next year.
-
Record Q2 revenue and strong cash flow highlight robust growth, driven by Pooph's expansion and new engineering contracts. Clyra Medical and PFAS water treatment are poised for significant future impact, while capital conservation strategies have minimized dilution.